For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.
GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
But can the novel antigen be targeted effectively? Immatics reckons it can, with the right dose and the right manufacturing process.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.